VE-2851: A Comprehensive Profile of a Novel Precision Oral Anticoagulant with a Differentiated Safety Profile

Executive Summary

VE-2851 is an orally available, direct thrombin inhibitor under development by Verseon Corporation for the prevention of strokes and heart attacks. It belongs to a novel drug class known as Precision Oral Anticoagulants (PROACs), which are being engineered to fundamentally address the primary limitation of existing antithrombotic therapies: the inherent risk of major bleeding. Currently designated as being in the "Clinical" stage of development, VE-2851 represents a second-generation candidate from Verseon's proprietary, computationally driven drug discovery platform.

The core value proposition of VE-2851 lies in its unique and highly differentiated mechanism of action. While it effectively inhibits thrombin to prevent the formation of fibrin-based blood clots, it has been specifically designed to spare thrombin's role in mediating platelet activation. This selective activity is hypothesized to uncouple antithrombotic efficacy from bleeding risk by preserving primary hemostasis, the body's initial response to vascular injury. This profile is supported by compelling preclinical data, which demonstrates that VE-2851 provides potent anticoagulation in animal models of thrombosis while exhibiting a dramatically improved safety profile. Notably, in rodent models, VE-2851 was associated with over 15 times less blood loss compared to apixaban, a market-leading direct oral anticoagulant (DOAC).

VE-2851 is being developed to address a significant unmet medical need within the cardiovascular disease (CVD) landscape. Its target indication is the treatment of a large patient population, estimated at over 185 million people globally, who require long-term combination therapy with both an anticoagulant and an antiplatelet agent. This includes patients with Acute Coronary Syndrome (ACS) or those with comorbid Atrial Fibrillation (AF) and Coronary Artery Disease (CAD). With current anticoagulants, such dual therapy is generally restricted to short-term use due to a prohibitively high risk of life-threatening bleeding. VE-2851, if its preclinical profile translates successfully to humans, could become the first anticoagulant suitable for safe, lifelong combination therapy in this high-risk population.

Further enhancing its potential clinical utility, VE-2851 has demonstrated a favorable pharmacokinetic profile in preclinical studies, including low renal clearance. This could make it a safer option for patients with impaired kidney function, a common comorbidity in the target patient demographic. Supported by a robust and recently expanded intellectual property portfolio, VE-2851 is a scientifically compelling asset. While it faces the inherent risks of clinical translation common to all early-stage drug candidates, its unique mechanism and strong preclinical evidence position it as a potential paradigm-shifting therapeutic capable of redefining the standard of care in antithrombosis.

Introduction to VE-2851 and the Verseon Discovery Platform

Verseon's Computationally Driven Discovery Engine

VE-2851 is a product of Verseon Corporation, a technology-based pharmaceutical company that employs a fundamentally different approach to drug discovery compared to traditional pharmaceutical development models.[1] Verseon's strategy is built upon a proprietary, computationally driven platform that integrates multiple advanced technologies to design novel drug candidates with unique therapeutic profiles.[2] This platform combines physics-based molecular modeling, artificial intelligence (AI), Deep Quantum Modeling, and novel optimization algorithms with a proprietary chemistry knowledge base.[1]

This integrated system allows Verseon's scientists to identify and design novel small molecules in silico that are predicted to bind to specific disease-causing target proteins with high affinity and selectivity.[1] By modeling these complex molecular interactions on the computer, the company can explore previously inaccessible areas of chemical space and prioritize the synthesis of only the most promising compounds for subsequent laboratory evaluation and clinical development.[2] This approach is designed to be more efficient and systematic than conventional methods, which often rely on high-throughput screening of existing compound libraries.

The Precision Oral Anticoagulant (PROAC) Program

The PROAC program is Verseon's most advanced clinical initiative and is focused on developing a new generation of anticoagulants for cardiovascular disease.[6] The central goal of the program is to overcome the most significant challenge in antithrombotic therapy: the risk of bleeding. This risk is particularly pronounced in patients who require combination therapy with both an anticoagulant and one or more antiplatelet drugs, such as aspirin or clopidogrel (Plavix).[1] While this dual therapy is clinically indicated for many high-risk patients, its long-term use is severely restricted by the dangerously heightened risk of major bleeding associated with all currently available anticoagulants.[1]

Verseon's PROACs are being developed to be the first anticoagulants safe enough for long-term, and potentially lifelong, co-administration with antiplatelet agents.[6] VE-2851 is the second lead candidate to emerge from this program, following the first-in-human compound, VE-1902.[1] The fact that Verseon's platform has generated multiple, chemically distinct drug candidates for the same therapeutic goal is a direct reflection of its underlying strategy. Unlike the common industry practice of advancing a single lead compound per program, Verseon's systematic approach allows for the creation of a portfolio of candidates for each disease area. This provides strategic depth, allows for the selection of optimized follow-on compounds, and mitigates the risk associated with the failure of a single asset.[1]

Pharmacological Profile: A Differentiated Mechanism of Action

Target and Binding Mechanism

VE-2851 is a highly potent and selective direct thrombin inhibitor (DTI), meaning it exerts its anticoagulant effect by directly binding to and inhibiting the activity of thrombin (also known as Factor IIa), a critical enzyme at the final stage of the coagulation cascade.[10] The binding mechanism of VE-2851, a hallmark of the PROAC class, involves a reversible covalent interaction with the active site of the thrombin enzyme.[8] This mode of action provides potent and durable inhibition while the drug is present but allows for the restoration of enzyme function upon drug clearance, differentiating it from irreversible inhibitors.

The Core Innovation: Sparing Platelet Function

The central innovation and primary differentiator of VE-2851 and the entire PROAC platform is its unique functional selectivity. Thrombin has multiple roles in hemostasis and thrombosis. It catalyzes the conversion of fibrinogen to fibrin, which forms the meshwork of a blood clot. It also serves as a potent activator of platelets, which are essential for forming the initial "plug" at a site of blood vessel injury (a process known as primary hemostasis). Current anticoagulants, including other DTIs like dabigatran, generally inhibit both of these functions, leading to effective prevention of pathological clots but also impairing the body's ability to stop bleeding from an injury.[10]

Verseon's PROACs have been engineered to separate these two effects. Preclinical studies have shown that while VE-2851 potently inhibits thrombin's cleavage of fibrinogen, it does not significantly inhibit thrombin-mediated platelet activation.[1] This "platelet-sparing" effect is the scientific foundation for the observed reduction in bleeding risk.[1] By leaving platelet function largely intact, VE-2851 is designed to allow for the formation of a primary hemostatic plug to prevent uncontrolled bleeding, while still preventing the formation of large, fibrin-rich pathological thrombi that cause strokes and heart attacks.

The degree of this selectivity is substantial. Preclinical data presented by Verseon demonstrates that VE-2851 has an approximately 200-fold reduced potency in inhibiting thrombin-mediated platelet activation when compared to other direct thrombin inhibitors. At the same time, it maintains a potency for inhibiting fibrinogen cleavage, thrombin-activatable fibrinolysis inhibitor (TAFI) activation, and protein C activation that is comparable to currently marketed novel oral anticoagulants (NOACs).[11] This suggests a highly precise mechanism of action that is not merely an incremental improvement but a functional re-engineering of how a DTI interacts with its target and the broader coagulation system.

Pharmacokinetic and Metabolic Profile

In addition to its novel mechanism, VE-2851 has been optimized for a favorable pharmacokinetic (PK) profile. Preclinical studies conducted in rats indicated that VE-2851 possesses good stability in both liver microsomes and plasma, and it demonstrated an improved overall PK profile compared to the first-generation PROAC, VE-1902.[11]

A particularly significant feature is its route of elimination. Unlike many existing anticoagulants that are cleared by the kidneys, VE-2851 is preferentially excreted through the feces.[11] This indicates low renal clearance, a highly desirable characteristic for an anticoagulant.[8] A large proportion of patients with cardiovascular disease, especially older adults, also suffer from varying degrees of renal impairment. For drugs that are heavily reliant on kidney function for elimination, this comorbidity can lead to drug accumulation, unpredictable anticoagulant effects, and a significantly increased risk of bleeding. A drug with low renal clearance, such as VE-2851, could offer a more predictable and safer treatment option for this substantial and vulnerable patient population.[11]

Preclinical Evidence: Efficacy and Safety Data

The therapeutic potential of VE-2851 is supported by a robust portfolio of preclinical data that demonstrates both potent antithrombotic efficacy and a superior safety profile compared to the current standard of care. These findings have been presented at major scientific conferences, including the American Heart Association (AHA) Scientific Sessions and the International Stroke Conference (ISC), and have been published in the peer-reviewed journal Circulation, lending them significant scientific credibility.[1]

Antithrombotic Efficacy in In Vivo Models

VE-2851 has demonstrated strong efficacy in multiple, well-established animal models of thrombosis that are driven by fibrin formation, the primary target of anticoagulation.[10] These include models of venous stasis thrombosis and arteriovenous (AV) shunt thrombosis.[11] In these studies, the antithrombotic efficacy of VE-2851 was shown to be comparable to that of existing NOACs, indicating that its novel mechanism does not compromise its ability to prevent pathological clot formation.[11]

Furthermore, as a second-generation compound within the PROAC program, VE-2851 represents a significant optimization over its predecessor. Preclinical data show that VE-2851 is approximately 5 times more potent as an anticoagulant than VE-1902, the first PROAC to enter clinical trials.[11] This demonstrates a clear and successful data-driven progression within Verseon's discovery and development process.

A Differentiated and Superior Safety Profile

The most compelling preclinical evidence for VE-2851 relates to its significantly reduced bleeding risk, which directly supports its core value proposition. In a head-to-head comparison using a rodent tail bleeding time test, VE-2851 demonstrated a markedly superior safety profile to apixaban (Eliquis), a leading Factor Xa inhibitor widely considered to have one of the best safety profiles among currently marketed DOACs. The results showed that VE-2851 was associated with greater than 15 times lower blood cell loss relative to apixaban.[11] Additionally, it produced a less pronounced extension of bleeding time when compared to other NOACs.[11]

This superior safety profile was mechanistically linked to the preservation of platelet function in vivo. In the AV shunt thrombosis model, where both anticoagulation and platelet activation can be measured, treatment with VE-2851 allowed for greater than 5 times higher maximum platelet activation compared to apixaban.[11] This finding provides strong evidence that VE-2851's unique platelet-sparing mechanism is operative in vivo and is the likely biological explanation for its reduced bleeding liability.

Feature/Metric	VE-2851	Apixaban (Comparator)	VE-1902 (Internal Comparator)
Drug Class	PROAC (Direct Thrombin Inhibitor)	Direct Factor Xa Inhibitor	PROAC (Direct Thrombin Inhibitor)
Mechanism	Reversible covalent thrombin inhibition; Platelet sparing	Direct Factor Xa inhibition	Reversible covalent thrombin inhibition; Platelet sparing
Relative Potency	5x more potent than VE-1902	N/A	Baseline
Efficacy (Thrombosis Models)	Comparable to NOACs	Standard of Care	Comparable to NOACs
Bleeding Risk (Blood Loss)	>15x lower vs. Apixaban	Standard of Care	Low Bleeding Profile
Platelet Activation In Vivo	>5x higher vs. Apixaban	Suppressed	Preserved
Renal Clearance	Low (Preferential Fecal Excretion)	Moderate	Very Low

Table 1: Comparative Preclinical Profile of VE-2851 vs. Standard-of-Care Anticoagulants. Data compiled from preclinical studies presented by Verseon.[8]

Clinical Development and Therapeutic Potential

Development Trajectory

VE-2851 was identified as Verseon's second anticoagulation candidate following the advancement of VE-1902. In late 2017, following the presentation of positive preclinical data, the company announced an expectation that VE-2851 would enter clinical trials in 2018.[13] By early 2019, Verseon confirmed that VE-1902 was in a Phase 1 trial and that it was continuing to advance VE-2851 for clinical trials, suggesting a potential shift from the original 2018 timeline.[1]

According to the most recent information available on Verseon's corporate website, the anticoagulation program, which encompasses both VE-1902 and VE-2851, is listed with a development stage of "Clinical".[5] This status confirms that the PROAC platform has successfully transitioned into human testing. However, the specific clinical status of VE-2851 itself is not publicly detailed. This ambiguity suggests either a strategic sequencing of the two assets, with VE-1902 being prioritized as the pathfinder molecule, or that the development of VE-2851 may have proceeded at a different pace than initially projected. Clarification of its current stage within the clinical pathway is a key point for future monitoring.

Target Patient Population and Unmet Need

VE-2851 is being developed to address a large and critically underserved segment of the cardiovascular patient population. The primary target group consists of patients who have clinical indications for long-term, concurrent therapy with both an anticoagulant and an antiplatelet agent.[1] This includes patients who have experienced an Acute Coronary Syndrome (ACS) and require an antiplatelet to prevent heart attacks, as well as an anticoagulant to prevent stroke. It also includes the growing number of patients who suffer from both Atrial Fibrillation (AF), which requires an anticoagulant to prevent stroke, and Coronary Artery Disease (CAD), which requires antiplatelet therapy.[6]

This patient population is substantial, estimated to comprise 185.7 million people worldwide. The potential global market for a safe combination therapy is valued at $203 billion per year.[6] The unmet medical need in this segment is profound and well-defined. Due to the dangerously high risk of major bleeding, combination antithrombotic therapy with current agents is generally limited to a maximum of 12 months post-event.[1] For patients who remain at high risk for both thrombotic and embolic events, clinicians are forced to make a difficult trade-off, often discontinuing one agent and leaving the patient sub-optimally protected against either heart attack or stroke. VE-2851 is being positioned as the first potential solution for safe, lifelong dual therapy, thereby addressing a clear gap in the current standard of care.[6]

Potential Clinical Advantages

If the differentiated preclinical profile of VE-2851 is validated in human trials, it could offer several significant clinical advantages:

1. Enabling Lifelong Dual Antithrombotic Therapy: The primary and most transformative advantage would be its ability to be safely co-administered with antiplatelet drugs for extended periods, allowing millions of high-risk patients to receive optimal, comprehensive protection against both heart attacks and strokes.
2. Improved Safety in Monotherapy: Even when used as a single agent, its superior preclinical safety profile suggests it could lead to a lower incidence of bleeding complications compared to currently available DOACs, improving the overall risk-benefit profile of anticoagulation.
3. Use in Comorbid Populations: The low renal clearance of VE-2851 would make it a particularly valuable option for the large subset of cardiovascular patients who also have chronic kidney disease, simplifying dosing and potentially reducing the risk of drug accumulation and associated bleeding events.[8]

This focused development strategy, targeting a well-defined area of high unmet need where existing drugs are contraindicated, represents a sound market entry approach. Rather than launching a direct, head-to-head challenge against entrenched blockbuster anticoagulants in the general market, success in the dual-therapy setting would establish a strong clinical foothold and clear therapeutic superiority in a niche that is, itself, a multi-billion dollar opportunity.

Market Landscape and Competitive Positioning

The Evolving Anticoagulant Market

The global market for anticoagulant therapies is a large, mature, and growing segment of the pharmaceutical industry, with a value estimated at over $35 billion in 2024 and projected to experience continued growth.[14] The treatment landscape has undergone a significant transformation over the past decade with the introduction and widespread adoption of Direct Oral Anticoagulants (DOACs), also referred to as Novel Oral Anticoagulants (NOACs). These agents have largely replaced the long-standing standard of care, warfarin (a vitamin K antagonist), due to major advantages in convenience, including fixed dosing, fewer food and drug interactions, and no requirement for routine coagulation monitoring.[16]

Within the DOAC class, Factor Xa inhibitors such as apixaban (Eliquis) and rivaroxaban (Xarelto) have become the dominant product type, capturing the majority of the market share due to their broad clinical applicability and favorable risk-benefit profiles in large outcomes trials.[16] However, despite these advances, the risk of bleeding remains the foremost clinical challenge and a significant restraint on the market's potential.[10] This concern is a primary driver for continued innovation in the field, with a focus on developing next-generation anticoagulants that can further improve upon the safety profile of current DOACs.

Competitive Positioning of VE-2851

VE-2851 is positioned not as an incremental "me-too" DOAC, but as a potentially disruptive agent with a unique value proposition centered on safety. Its competitive differentiation is derived directly from its novel platelet-sparing mechanism of action.[8]

• Primary Competitive Advantage: The key differentiator for VE-2851 is its potential to be the first anticoagulant proven safe for long-term combination therapy with antiplatelet agents. In this specific, large market segment, current DOACs are not strong competitors due to their safety liabilities, creating a significant opportunity for a drug with a superior bleeding profile.[1]
• Secondary Advantage: Its favorable pharmacokinetic profile, particularly its low renal clearance, provides a secondary competitive advantage in the treatment of patients with renal impairment, a population where clinicians exercise caution when prescribing certain existing DOACs.[8]

Intellectual Property Foundation

A strong intellectual property (IP) portfolio is critical for protecting the innovation and securing the commercial potential of a novel drug candidate. Verseon has been diligent in establishing robust patent protection for its PROAC program. In January 2017, the United States Patent and Trademark Office (USPTO) granted the company US Patents No. 9,533,967 and 9,533,970, which cover various compounds related to its anticoagulant program.[12]

More recently and more specifically, in January 2024, the USPTO issued a new patent for Verseon titled "Thrombin Inhibitors, Formulations, and Uses Thereof" (US Patent No. 11,865,110 B2).[2] This patent further extends the IP protection for the company's novel class of thrombin inhibitors. Crucially, the patent covers the unique mechanism of action that underpins the PROACs' value proposition: the ability to prevent the formation of dangerous blood clots without unacceptably increasing the risk of bleeding, owing to the preservation of thrombin-mediated platelet activation.[2] This recent and specific patent grant, with an adjusted expiration in 2040, provides a strong foundation for long-term market exclusivity for VE-2851 and other related compounds in the PROAC class.[21]

Synthesis and Future Outlook

Consolidated Strengths and Potential Risks

VE-2851 emerges from this analysis as a highly promising drug candidate with a clear and compelling therapeutic rationale. Its potential is defined by a combination of significant strengths, balanced by the inherent risks of early-stage pharmaceutical development.

Strengths:

1. Novel, Differentiated Mechanism of Action: The platelet-sparing effect of VE-2851 represents a true scientific innovation. It is a direct and rational approach to solving the fundamental trade-off between efficacy and bleeding that has constrained antithrombotic therapy for decades.
2. Compelling Preclinical Safety Data: The quantitative preclinical evidence, particularly the demonstration of >15-fold lower blood loss compared to a market-leading competitor like apixaban, is exceptionally strong. This provides a clear, measurable, and clinically meaningful benchmark for success.
3. Well-Defined, Large Unmet Medical Need: The target indication of long-term combination therapy addresses a massive patient population that is currently underserved due to the safety limitations of existing drugs. This provides a clear and strategically sound path to market entry.
4. Favorable Pharmacokinetic Profile: The low renal clearance is a significant secondary advantage that could expand its use to patients with chronic kidney disease, a common and challenging comorbidity.
5. Robust Intellectual Property: Verseon has secured recent and specific patent protection covering the novel compounds and their unique mechanism of action, ensuring a foundation for future commercial exclusivity.

Risks and Unanswered Questions:

1. Clinical Translation Risk: The single greatest uncertainty is whether the remarkable preclinical safety and efficacy profile of VE-2851 will translate successfully into human clinical trials. This is the fundamental risk for any drug candidate at this stage of development.
2. Ambiguous Development Timeline: The lack of public clarity regarding the specific clinical status of VE-2851, and the apparent shift from its initial projected timeline, raises questions about its development path. Understanding whether this represents a strategic sequencing or an unforeseen hurdle is critical.
3. Evolving Competitive Landscape: While VE-2851's mechanism is unique, the broader goal of safer anticoagulation is being pursued by other companies through different mechanisms (e.g., Factor XI inhibitors). The long-term competitive environment will continue to evolve during VE-2851's development.
4. Corporate and Financial Risk: As a clinical-stage company, Verseon's ability to secure the substantial funding required for late-stage Phase 2 and Phase 3 trials is a key consideration for its long-term success.

Concluding Remarks

VE-2851 is a highly promising, second-generation precision oral anticoagulant that has emerged from a novel and seemingly productive computational drug discovery platform. Its core innovation—the mechanistic separation of antithrombotic efficacy from the disruption of primary hemostasis—is supported by compelling preclinical evidence and is aimed squarely at a significant and well-defined unmet medical need.

While the journey through clinical development is long and fraught with risk, VE-2851 represents a potential paradigm shift in the management of cardiovascular disease. Its progression through the clinic will be a key catalyst to watch. Should the differentiated profile observed in preclinical studies be replicated in human subjects, VE-2851 would be strongly positioned as a first-in-class and best-in-class therapeutic. It holds the potential to transform the standard of care for millions of patients worldwide who are at high risk of both thrombotic and bleeding events, finally offering a solution that does not force a compromise between preventing heart attacks and strokes and ensuring patient safety. The immediate focus for any further due diligence should be on obtaining clarity regarding its precise clinical development status and the timeline for future data readouts.

Works cited

1. Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding at International Stroke Conference - FirstWord Pharma, accessed October 28, 2025, https://firstwordpharma.com/story/4740195
2. US Patent Issued for Verseon PROAC, accessed October 28, 2025, https://www.verseon.com/news-verseon-gains-us-patent-protection-for-compounds-that-could-eliminate-bleeding-risks-of-current-anticoagulants.html
3. Verseon Gains US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants - PR Newswire, accessed October 28, 2025, https://www.prnewswire.com/news-releases/verseon-gains-us-patent-protection-for-compounds-that-could-eliminate-bleeding-risks-of-current-anticoagulants-302042794.html
4. Meet ADITYO PRAKASH(CEO of Verseon), accessed October 28, 2025, https://www.verseon.com/news-ai-in-healthcare-magazine-marktechpost_content.html
5. Verseon: Precision Engineered Novel Disease Treatments, accessed October 28, 2025, https://www.verseon.com/
6. Strokes & Heart Attacks | Verseon, accessed October 28, 2025, https://www.verseon.com/pipeline-1-anticoagulation.html
7. Verseon's Atomic-Level Drug Design is Changing the Paradigm of ..., accessed October 28, 2025, https://www.biospace.com/verseon-s-atomic-level-drug-design-is-changing-the-paradigm-of-drug-discovery
8. Verseon, accessed October 28, 2025, https://www.verseon.com/news-efficacyanticoagulant_content.html
9. Fast Drug Development Pipeline - Verseon, accessed October 28, 2025, https://www.verseon.com/pipeline.html
10. Verseon Corp. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed October 28, 2025, https://synapse.patsnap.com/organization/91ae957a2ffaa6e3fa560db073579648
11. Abstract 19503: An Improved Potent Direct Thrombin Inhibitor ..., accessed October 28, 2025, https://www.ahajournals.org/doi/10.1161/circ.136.suppl_1.19503
12. Verseon Granted U.S. Patents Covering Its Novel Serine Protease Inhibitors - BioSpace, accessed October 28, 2025, https://www.biospace.com/verseon-granted-u-s-patents-covering-its-novel-serine-protease-inhibitors
13. News for November 2017 - Drug Discovery Today, accessed October 28, 2025, http://www.drugdiscoverytoday.com/news/2017/11/
14. Anticoagulant Market Expected to Double, Touching USD 66.1 Billion by 2033, accessed October 28, 2025, https://media.market.us/anticoagulant-market-news-2025/
15. Anticoagulants Market Size & Share | Industry Report, 2030 - Grand View Research, accessed October 28, 2025, https://www.grandviewresearch.com/industry-analysis/anticoagulants-market-report
16. Direct Oral Anticoagulants Market Size, Share, Trends, Report 2025 ..., accessed October 28, 2025, https://www.reportsandinsights.com/report/direct-oral-anticoagulants-market
17. Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide - MDPI, accessed October 28, 2025, https://www.mdpi.com/2077-0383/14/9/2914
18. Direct Oral Anticoagulants (DOACs) Device market | Industry Report, 2034, accessed October 28, 2025, https://www.polarismarketresearch.com/industry-analysis/direct-oral-anticoagulants-doacs-device-market
19. Direct Oral Anticoagulants Market Captures USD 51.20 Billion in 2025 - Towards Healthcare, accessed October 28, 2025, https://www.towardshealthcare.com/insights/direct-oral-anticoagulants-doacs-market-sizing
20. Novel oral anticoagulants and reversal agents: Considerations for clinical development - American College of Cardiology, accessed October 28, 2025, https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools%20and%20Practice%20Support/Quality%20Programs/Anticoagulation-roundtable/2-Novel-Oral-Anticoagulants-and-reversal-agents.pdf
21. US11865110B2 - Thrombin inhibitors, formulations, and uses thereof - Google Patents, accessed October 28, 2025, https://patents.google.com/patent/US11865110B2/en